Accessibility Menu
Novartis Ag logo

Novartis Ag

(OTC) NVSEF

Current Price$151.90
Market Cap$278.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+325%
5 Year+96%
1 Year+32%
1 Month+5%
Novartis Ag last closing stock price
MetricPriceDate
Last closeUSD 151.902026-07-17
Novartis Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.14%USD 153.652026-07-10
1 month+4.76%USD 145.002026-06-17
3 month+0.59%USD 151.002026-04-17
Year to date+13.51%USD 133.822025-12-31
1 year+32.01%USD 115.072025-07-16
3 year+61.39%USD 94.122023-07-18
5 year+96.47%USD 77.312021-07-15
Since inception+324.54%USD 35.782003-06-26

Novartis Ag Financials at a Glance

Market Cap

$278.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$55.50B

Net Income (TTM)

$13.49B

EPS (TTM)

$6.98

P/E Ratio

21.62

Dividend

$4.74

Beta (Volatility)

0.07 (Low)

Price

$151.90

Volume

38

Open

$151.90

Previous Close

$151.90

Daily Range

$151.90 - $151.90

52-Week Range

$110.74 - $171.29

Estimated Earnings Date

Jul 21, 2026

NVSEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novartis Ag

Novartis AG is a leading global pharmaceutical company based in Basel, Switzerland, focused on the research, development, manufacturing, and commercialization of healthcare products. Established in 1996, Novartis operates through two main divisions: Innovative Medicines and Sandoz, providing a diverse range of therapeutic solutions.

Products and Services
  • Innovative Medicines: Advanced prescription medications across various therapeutic areas
  • Sandoz: Generic and biosimilar products, including antibiotics and active pharmaceutical ingredients
  • Strategic collaborations: Partnerships for drug development and commercialization
Growth Outlook
  • Revenue of $12.86 billion in Q1 2026, showcasing strong market demand
  • Net income of $3.09 billion in Q1 2026, reflecting robust profitability
  • Consistent R&D investment, with $2.74 billion allocated in Q1 2026 for future innovations
Financial Highlights
  • Trailing twelve months (TTM) revenue of $54.5 billion, indicating steady growth
  • Net profit margin of 24.3% TTM, demonstrating effective cost management
  • Dividend yield of 2.97% TTM, providing attractive returns to shareholders
Novartis AG stands out in the pharmaceutical industry due to its commitment to innovation and extensive product portfolio. The company's focus on research and development ensures a pipeline of new therapies, while its strong financial performance highlights its operational efficiency. With a solid market presence and strategic partnerships, Novartis is well-positioned for continued growth in the evolving healthcare landscape.
AI Generated • Jun 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

75,267

CEO

Vasant Narasimhan, MD

Website

www.novartis.com

Headquarters

Basel, BS 4056, CH

NVSEF Financials

Key Financial Metrics (TTM)

Gross Margin

75.13%

Operating Margin

29.88%

Net Income Margin

24.31%

Return on Equity

31.54%

Return on Capital

21.41%

Return on Assets

11.34%

Earnings Yield

4.63%

Dividend Yield

3.12%

Payout Ratio

61.00%

Stock Overview

Market Cap

$278.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.83B

Volume

38

Avg. Volume

37.62K

Financials (TTM)

Gross Profit

$41.69B

Operating Income

$16.81B

EBITDA

$22.96B

Operating Cash Flow

$18.99B

Capital Expenditure

-$2.35B

Free Cash Flow

$16.63B

Cash & ST Invst.

$7.02B

Total Debt

$47.25B

Novartis Ag Performance Analysis

Novartis Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 42,206,000,000-18.2%
20232023-12-31USD 45,440,000,0007.7%
20242024-12-31USD 50,317,000,00010.7%
20252025-12-31USD 54,532,000,0018.4%
Novartis Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.9%
Q32025-09-30-3.2%
Q42025-12-31-6.4%
Q12026-03-31-4.4%
Novartis Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.17-70.2%
20232023-12-31USD 7.10124.2%
20242024-12-31USD 5.87-17.3%
20252025-12-31USD 7.1521.9%
Novartis Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3013.2%
Q32025-09-30-2.9%
Q42025-12-31-37.0%
Q12026-03-3128.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$12.86B

-5.6%

Gross Profit

$9.49B

-8.7%

Gross Margin

73.78%

N/A

Market Cap

$278.05BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.69M

N/A

Employees

75,267

N/A

Net Income

$3.09B

-15.5%

EBITDA

$4.83B

-17.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.02B

-2.5%

Total Debt

$47.25B

+51.1%

Accounts Receivable

$9.65B

+10.7%

Inventory

$6.32B

+8.5%

Long Term Debt

$39.32B

+69.3%

Short Term Debt

$7.89B

-1.9%

Return on Assets

11.34%

N/A

Return on Invested Capital

18.96%

N/A

Free Cash Flow

$3.27B

-3.7%

Operating Cash Flow

$3.60B

-1.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RHHVFRoche Holding AG
$405.00-0.99%
NONOFNovo Nordisk A/S
$50.74+0.71%
RHHBYRoche Holding AG
$51.60+0.29%
RHHBFRoche Holding AG
$435.00+2.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$95.04-0.02%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%
TAT&T
$21.81-0.01%

Questions About NVSEF

What is the current price of Novartis Ag?

Novartis Ag is trading at $151.90 per share.

What is the 52-week range for Novartis Ag?

Over the past 52 weeks, Novartis Ag has traded between $110.74 and $171.29.

How much debt does Novartis Ag have?

As of the most recent reporting period, Novartis Ag reported total debt of $47.00B.

How much cash does Novartis Ag have on hand?

Novartis Ag reported $6.88B in cash and cash equivalents in its most recent financial results.

What is Novartis Ag’s dividend yield?

Novartis Ag currently has a dividend yield of 3.12%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services